tempol / MotoGen - LARVOL DELTA

Role of the Polyol Pathway in Locomotor Recovery and Wallerian Degeneration after Spinal Cord Contusion Injury. (PubMed, Neurotrauma Rep) - "We tested individual treatments with AR inhibitors (sorbinil or ARI-809), SDH inhibitor (CP-470711), superoxide dismutase mimetic (tempol), or combined sorbinil and tempol...Unexpectedly, contusion increased spinal cord levels of glucose, the primary polyol pathway substrate. These results support roles for spinal glucose elevation and tissue glucotoxicity by the polyol pathway after spinal cord contusion injury that results in ROS-mediated axonal degeneration."

Journal • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Orthopedics • Thrombosis • AKR1B1

The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: The University of Texas at Arlington; Recruiting ➔ Completed; N=50 ➔ 24; Trial completion date: Oct 2019 ➔ Feb 2020; Trial primary completion date: Oct 2019 ➔ Feb 2020

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Cardiovascular

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19 (GlobeNewswire) - "Adamis Pharmaceuticals Corporation...announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19)....In consideration for Matrix providing the exclusive rights under its patent rights and related know-how relating to Tempol within the licensed fields, Adamis paid Matrix $250,000 following signing of the definitive agreement. Adamis will also issue to Matrix 1,000,000 shares of Adamis convertible preferred stock..."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer (clinicaltrials.gov) - P; N=N/A; Available; Sponsor: Matrix Biomed, Inc.

Clinical • New trial

Treatment of Radiation and Cisplatin Induced Toxicities With Tempol (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Matrix Biomed, Inc.; Trial completion date: May 2020 ➔ Oct 2021; Trial primary completion date: May 2020 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date

Treatment of Radiation and Cisplatin Induced Toxicities With Tempol (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Matrix Biomed, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Treatment of Radiation and Cisplatin Induced Toxicities With Tempol (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Matrix Biomed, Inc.; Trial completion date: Oct 2019 ➔ May 2020; Trial primary completion date: Oct 2019 ➔ May 2020

Clinical • Trial completion date • Trial primary completion date

The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: The University of Texas at Arlington; Not yet recruiting ➔ Recruiting

Enrollment open